For example, a MAGE-A3 immunotherapeutic comprising recombinant MAGE-A3 protein given with a proprietary adjuvant, A15 (GlaxoSmithKline), showed promising clinical benefit in a phase 2 study in melanoma patients [79]. The gene discussed is MAGEA3; the disease is melanoma.